NASDAQ, STEM - Stemcells Inc
StemCells, Inc. is engaged in the discovery and development of cell-based
therapeutics to treat damage to, or degeneration of, major organ systems. Our
aim is to restore or support organ function, improve patients? lives and reduce
the substantial health care costs associated with these diseases and disorders
by identifying and developing stem and progenitor cells as potential therapeutic
agents. We currently have product development programs for two cell types: the
human neural stem cell and human liver engrafting cells. In our CNS Program, we
are conducting a Phase I clinical trial to evaluate the safety and preliminary
efficacy of our HuCNS-SC? product candidate (purified human neural stem cells)
as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis
(NCL), two forms of a group of disorders often referred to as Batten disease. We
have completed enrollment and dosing in this six-patient trial and expect it to
be completed in early 2009. ...
Read SEC Filing on NASDAQ.com »